Interpretation of expert consensus on the management of hypertension in young and middle-aged Chinese population_Chinese Journal of Evidence-Based Medicine

Authors：

FANG Xiang ¹ , PAN Xiaorong ¹ , CHENG Yisong ³ , JIA Yu ² , YANG Rong ¹ , LI Fanghui ³ , YAO Yi ¹ ,  LI Dongze ² ,  LIAO Xiaoyang ¹

1. General Practice Unit and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;
2. Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;
3. Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;

Corresponding author：

LI Dongze, Email: dongze.li@ymail.com; LIAO Xiaoyang, Email: 625880796@qq.com

Keywords：

Hypertension; Young and middle-aged population; Management; Consensus; Interpretation

DOI：

10.7507/1672-2531.202001091

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The management of middle-aged and youth hypertension has become a challenge in clinical practice. The hypertension group of the Chinese Society of Cardiology published the expert consensus on the management of hypertension in young and middle-aged Chinese population in 2019. This paper interprets the key contents of the consensus and provides references for management of young and middle-aged hypertension.

Citation： FANG Xiang, PAN Xiaorong, CHENG Yisong, JIA Yu, YANG Rong, LI Fanghui, YAO Yi, LI Dongze, LIAO Xiaoyang. Interpretation of expert consensus on the management of hypertension in young and middle-aged Chinese population. Chinese Journal of Evidence-Based Medicine, 2020, 20(7): 753-758. doi: 10.7507/1672-2531.202001091 Copy

1.	Liu J, Lu X, Chen L, et al. Expert consensus on the management of hypertension in the young and middle-aged Chinese population. Int J Clin Pract, 2019, 73(12): e13426.
2.	Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China hypertension survey, 2012-2015. Circulation, 2018, 137(22): 2344-2356.
3.	Booth JN 3rd, Li J, Zhang L, et al. Trends in prehypertension and hypertension risk factors in US Adults: 1999-2012. Hypertension, 2017, 70(2): 275-284.
4.	Qi Y, Han X, Zhao D, et al. Long-term cardiovascular risk associated with stage 1 hypertension defined by the 2017 ACC/AHA hypertension guideline. J Am Coll Cardiol, 2018, 72(11): 1201-1210.
5.	Yano Y, Stamler J, Garside DB, et al. Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol, 2015, 65(4): 327-335.
6.	Guo J, Zhu YC, Chen YP, et al. The dynamics of hypertension prevalence, awareness, treatment, control and associated factors in Chinese adults: results from CHNS 1991-2011. J Hypertens, 2015, 33(8): 1688-1696.
7.	Zhang Y, Moran AE. Trends in the prevalence, awareness, treatment, and control of hypertension among young adults in the United States, 1999 to 2014. Hypertension, 2017, 70(4): 736-742.
8.	Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension, 1983, 5(1): 86-99.
9.	White M, Leenen FH. Effects of age on cardiovascular responses to adrenaline in man. Br J Clin Pharmacol, 1997, 43(4): 407-414.
10.	符春晖, 严华, 陆永光, 等. 原发性高血压病患者肾素-血管紧张素-醛固酮系统活性的影响因素. 中华实用诊断与治疗杂志, 2011, 25(7): 633-635.
11.	Suvila K, McCabe EL, Lehtonen A, et al. Early onset hypertension is associated with hypertensive end-organ damage already by MidLife. Hypertension, 2019, 74(2): 305-312.
12.	中国老年医学学会高血压分会, 国家老年疾病临床医学研究中心中国老年心血管病防治联盟. 中国老年高血压管理指南2019. 中华老年多器官疾病杂志, 2019, 18(2): 6-31.
13.	Yoon SS, Gu Q, Nwankwo T, et al. Trends in blood pressure among adults with hypertension: United States, 2003 to 2012. Hypertension, 2015, 65(1): 54-61.
14.	Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) Ⅲ. Hypertension, 2001, 37(3): 869-874.
15.	段秀芳, 吴锡桂, 顾东风. 我国成人收缩期和舒张期高血压的分布. 高血压杂志, 2005, 13(8): 500-503.
16.	Martell-Claros N, Galgo-Nafria A, OPENJOVEN study group. Cardiovascular risk profile of young hypertensive patients: the OPENJOVEN study. Eur J Prev Cardiol, 2012, 19(3): 534-540.
17.	Ostchega Y, Zhang G, Kit BK, et al. Factors associated with home blood pressure monitoring among US adults: National Health and Nutrition Examination Survey, 2011-2014. Am J Hypertens, 2017, 30(11): 1126-1132.
18.	杨晓辉, 姚崇华. 北京市社区就诊高血压患者家庭自测血压情况及对血压控制的影响. 中华高血压杂志, 2010, 18(8): 739-743.
19.	Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Euro Heart J, 2014, 35(19): 1245-1254.
20.	中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版). 中国心血管杂志, 2019, 24(1): 24-56.
21.	中华医学会心血管病学分会精准心血管病学学组, 中国医疗保健国际交流促进会, 精准心血管病分会, 等. 单基因遗传性心血管疾病基因诊断指南. 中华心血管病杂志, 2019, 47(3): 175-196.
22.	Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J, 2018, 39(33): 3021-3104.
23.	Allen N, Berry JD, Ning H, et al. Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation, 2012, 125(1): 37-44.
24.	Sundström J, Neovius M, Tynelius P, et al. Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts. BMJ, 2011, 342: d643.
25.	Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: The China-PAR project (Prediction for ASCVD Risk in China). Circulation, 2016, 134(19): 1430-1440.
26.	Li Y, Thijs L, Zhang ZY, et al. Opposing age-related trends in absolute and relative risk of adverse health outcomes associated with out-of-office blood pressure. Hypertension, 2019, 74(6): 1333-1342.
27.	Williams B. High blood pressure in young people and premature death. BMJ, 2011, 342: d1104.
28.	Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens, 2011, 24(11): 1164-1180.
29.	Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs-overview and meta-analyses. J Hypertens, 2015, 33(7): 1321-1341.
30.	Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. BMJ, 2011, 343: d4891.
31.	Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich), 2014, 16(1): 14-26.
32.	Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens, 2018, 36(8): 1637-1647.
33.	van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158, 998 patients. Eur Heart J, 2012, 33(16): 2088-2097.
34.	Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens, 2012, 30(6): 1047-1055.

1. Liu J, Lu X, Chen L, et al. Expert consensus on the management of hypertension in the young and middle-aged Chinese population. Int J Clin Pract, 2019, 73(12): e13426.
2. Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China hypertension survey, 2012-2015. Circulation, 2018, 137(22): 2344-2356.
3. Booth JN 3rd, Li J, Zhang L, et al. Trends in prehypertension and hypertension risk factors in US Adults: 1999-2012. Hypertension, 2017, 70(2): 275-284.
4. Qi Y, Han X, Zhao D, et al. Long-term cardiovascular risk associated with stage 1 hypertension defined by the 2017 ACC/AHA hypertension guideline. J Am Coll Cardiol, 2018, 72(11): 1201-1210.
5. Yano Y, Stamler J, Garside DB, et al. Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol, 2015, 65(4): 327-335.
6. Guo J, Zhu YC, Chen YP, et al. The dynamics of hypertension prevalence, awareness, treatment, control and associated factors in Chinese adults: results from CHNS 1991-2011. J Hypertens, 2015, 33(8): 1688-1696.
7. Zhang Y, Moran AE. Trends in the prevalence, awareness, treatment, and control of hypertension among young adults in the United States, 1999 to 2014. Hypertension, 2017, 70(4): 736-742.
8. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension, 1983, 5(1): 86-99.
9. White M, Leenen FH. Effects of age on cardiovascular responses to adrenaline in man. Br J Clin Pharmacol, 1997, 43(4): 407-414.
10. 符春晖, 严华, 陆永光, 等. 原发性高血压病患者肾素-血管紧张素-醛固酮系统活性的影响因素. 中华实用诊断与治疗杂志, 2011, 25(7): 633-635.
11. Suvila K, McCabe EL, Lehtonen A, et al. Early onset hypertension is associated with hypertensive end-organ damage already by MidLife. Hypertension, 2019, 74(2): 305-312.
12. 中国老年医学学会高血压分会, 国家老年疾病临床医学研究中心中国老年心血管病防治联盟. 中国老年高血压管理指南2019. 中华老年多器官疾病杂志, 2019, 18(2): 6-31.
13. Yoon SS, Gu Q, Nwankwo T, et al. Trends in blood pressure among adults with hypertension: United States, 2003 to 2012. Hypertension, 2015, 65(1): 54-61.
14. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) Ⅲ. Hypertension, 2001, 37(3): 869-874.
15. 段秀芳, 吴锡桂, 顾东风. 我国成人收缩期和舒张期高血压的分布. 高血压杂志, 2005, 13(8): 500-503.
16. Martell-Claros N, Galgo-Nafria A, OPENJOVEN study group. Cardiovascular risk profile of young hypertensive patients: the OPENJOVEN study. Eur J Prev Cardiol, 2012, 19(3): 534-540.
17. Ostchega Y, Zhang G, Kit BK, et al. Factors associated with home blood pressure monitoring among US adults: National Health and Nutrition Examination Survey, 2011-2014. Am J Hypertens, 2017, 30(11): 1126-1132.
18. 杨晓辉, 姚崇华. 北京市社区就诊高血压患者家庭自测血压情况及对血压控制的影响. 中华高血压杂志, 2010, 18(8): 739-743.
19. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Euro Heart J, 2014, 35(19): 1245-1254.
20. 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版). 中国心血管杂志, 2019, 24(1): 24-56.
21. 中华医学会心血管病学分会精准心血管病学学组, 中国医疗保健国际交流促进会, 精准心血管病分会, 等. 单基因遗传性心血管疾病基因诊断指南. 中华心血管病杂志, 2019, 47(3): 175-196.
22. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J, 2018, 39(33): 3021-3104.
23. Allen N, Berry JD, Ning H, et al. Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation, 2012, 125(1): 37-44.
24. Sundström J, Neovius M, Tynelius P, et al. Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts. BMJ, 2011, 342: d643.
25. Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: The China-PAR project (Prediction for ASCVD Risk in China). Circulation, 2016, 134(19): 1430-1440.
26. Li Y, Thijs L, Zhang ZY, et al. Opposing age-related trends in absolute and relative risk of adverse health outcomes associated with out-of-office blood pressure. Hypertension, 2019, 74(6): 1333-1342.
27. Williams B. High blood pressure in young people and premature death. BMJ, 2011, 342: d1104.
28. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens, 2011, 24(11): 1164-1180.
29. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs-overview and meta-analyses. J Hypertens, 2015, 33(7): 1321-1341.
30. Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. BMJ, 2011, 343: d4891.
31. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich), 2014, 16(1): 14-26.
32. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens, 2018, 36(8): 1637-1647.
33. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158, 998 patients. Eur Heart J, 2012, 33(16): 2088-2097.
34. Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens, 2012, 30(6): 1047-1055.

Chinese Journal of Evidence-Based Medicine

Interpretation of expert consensus on the management of hypertension in young and middle-aged Chinese population

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content